Zifam Pyrex Myanmar Co., Ltd. develops and manufactures a comprehensive portfolio of pharmaceutical products designed to address both acute medical conditions and the growing burden of non-communicable diseases (NCDs).

Globally, NCDs such as cardiovascular diseases, diabetes, chronic respiratory conditions, and neurological disorders account for the majority of morbidity and mortality, and this trend is increasingly reflected in Myanmar, where lifestyle changes and aging populations are driving a steady rise in chronic disease prevalence. In this context, access to safe, effective, and high-quality medicines is essential for improving patient outcomes and reducing long-term healthcare burden.

The company’s core strength lies in its beta-lactam antibiotic range, produced in dedicated, segregated facilities to ensure strict compliance with WHO-GMP standards and to prevent cross-contamination. These life-saving antibiotics play a vital role in the effective management of infectious diseases, enabling timely intervention, reducing complications, and supporting faster patient recovery. With multiple dosage forms—including tablets, capsules, dry syrups, and dry powder injections—these products are designed to meet the needs of diverse patient populations, from outpatient care to hospital settings.

In parallel, Zifam Pyrex Myanmar’s General Block portfolio is strategically developed to address the rising burden of NCDs. The portfolio covers key therapeutic areas such as cardiovascular diseases, diabetes and metabolic disorders, gastroenterology, neurology, and other chronic conditions, supporting long-term disease control, prevention of complications, and improved patient adherence. By incorporating both established therapies and newer-generation molecules, the company enables healthcare professionals to deliver more effective, targeted, and sustainable treatment approaches.

All products are developed using validated formulations and optimized manufacturing processes, supported by rigorous testing through an ISO/IEC 17025 accredited laboratory. High-quality raw materials sourced from globally approved suppliers, combined with strict in-process controls and compliance with international pharmacopoeial standards (USP, BP, Ph. Eur.), ensure consistent efficacy, safety, and reliability. This integrated system supports confident clinical use and ensures that patients receive medicines that are dependable throughout their treatment journey.

Through the integration of essential antibiotics and advanced therapies for chronic diseases, Zifam Pyrex Myanmar contributes to strengthening healthcare systems, supporting clinical decision-making, and improving patient outcomes, while addressing both immediate treatment needs and the long-term challenges posed by NCDs in Myanmar and globally.